Cue Biopharma Announces Board and Executive Changes
Ticker: CUE · Form: 8-K · Filed: Mar 12, 2025 · CIK: 1645460
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Cue Biopharma shakes up board & exec comp. Big changes coming?
AI Summary
Cue Biopharma, Inc. announced on March 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about future strategy and performance.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- March 10, 2025 (date) — Date of earliest event reported
- March 12, 2025 (date) — Date of report
FAQ
Who are the specific officers or directors that have departed from Cue Biopharma?
The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.
When did the changes in directors and officers take effect?
The earliest event reported is March 10, 2025, and the filing is as of March 12, 2025.
What specific changes were made to the compensatory arrangements of certain officers?
The filing states that there were updates to compensatory arrangements for certain officers, but the details of these changes are not provided in the excerpt.
What is the primary business of Cue Biopharma, Inc.?
Cue Biopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc. is headquartered at 40 Guest Street, Boston, Massachusetts, 02135.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 12, 2025 regarding Cue Biopharma, Inc. (CUE).